COVID has pumped this stock to overbought.
Teladoc Health now anticipates revenues for the first quarter of 2020 to be in the range of $180-181 million, up 40% year over year. Adjusted EBITDA is expected in the band of $10-11 million compared with $1.2 million in the first quarter of 2019.
-NFA
Teladoc Health now anticipates revenues for the first quarter of 2020 to be in the range of $180-181 million, up 40% year over year. Adjusted EBITDA is expected in the band of $10-11 million compared with $1.2 million in the first quarter of 2019.
-NFA
Note
4.17.2020 Short
My opinions only not trading advice.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
My opinions only not trading advice.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.